Zhong Ling, Su Jia, Zhou Xiyuan, Wan Huiying
Department of Dermatology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
School of Medicine and Life Science, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Nutr. 2025 Jul 15;12:1587348. doi: 10.3389/fnut.2025.1587348. eCollection 2025.
Previous meta-analyses of multiple studies have suggested that probiotics supplementation plays a role in reducing the risk of atopic dermatitis (AD). However, the conclusions of these studies remain controversial.
We conducted an umbrella review of meta-analyses to comprehensively analyze and evaluate the evidence regarding the association between probiotics and AD. We searched PubMed, Web of Science, Embase, Spous, and Cochrane Library databases for meta-analyses and systematic reviews up to October 2024. Our selection criteria encompassed meta-analyses of cohort studies, case-control studies, and randomized controlled clinical trials investigating the associations between probiotics and the risk of AD. We also assessed the levels of evidence for these associations using the AMSTAR 2 criteria.
A total of 32 eligible articles, including 126 meta-analyses, were included for qualitative synthesis in this umbrella review. The results indicate that probiotics supplementation is associated with a reduced risk of AD. The subgroup analysis indicates that supplementation with spp., single-strain, and multi-strain probiotics is associated with a reduced risk of AD, with multi-strain formulations potentially demonstrating more pronounced effects. Furthermore, both combined prenatal and postnatal supplementation, as well as postnatal supplementation alone, contribute to a reduction in AD risk.
Probiotics supplementation may help reduce the risk of AD, with early-life administration playing a key role. Future research should focus on well-designed randomized controlled trials that account for potential sources of bias in order to provide evidence-based public health recommendations.
PROSPERO (International00 Prospective Register of Systematic Reviews) under the registration number CRD42024599789. The publicly accessible registration record is available at: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024599789.
先前对多项研究的荟萃分析表明，补充益生菌在降低特应性皮炎（AD）风险方面发挥作用。然而，这些研究的结论仍存在争议。
我们对荟萃分析进行了一项汇总分析，以全面分析和评估有关益生菌与AD之间关联的证据。我们在PubMed、科学网、Embase、Spous和Cochrane图书馆数据库中检索截至2024年10月的荟萃分析和系统评价。我们的选择标准包括对队列研究、病例对照研究和随机对照临床试验的荟萃分析，这些研究调查了益生菌与AD风险之间的关联。我们还使用AMSTAR 2标准评估了这些关联的证据水平。
本汇总分析共纳入32篇符合条件的文章，包括126项荟萃分析，进行定性综合分析。结果表明，补充益生菌与AD风险降低相关。亚组分析表明，补充 属、单菌株和多菌株益生菌与AD风险降低相关，多菌株制剂可能显示出更显著的效果。此外，产前和产后联合补充以及仅产后补充均有助于降低AD风险。
补充益生菌可能有助于降低AD风险，早期补充起关键作用。未来的研究应侧重于设计良好的随机对照试验，考虑潜在的偏倚来源，以便提供基于证据的公共卫生建议。
PROSPERO（国际系统评价前瞻性注册库），注册号CRD42024599789。可公开访问的注册记录可在以下网址获取：https://www.crd.york.ac.uk/PROSPERO/view/CRD42024599789 。
